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neuro-endocrine origin, usually arising on sun-exposed parts of the skin. Only four
cases of intra-oral MCC excluding the lips are reported with a maximum survival
of 26 months. A new case with a MCC on the right glossopharyngeal fold is pre-
sented. Because of the aggressive behaviour and the fact that wide excision with
3 cm resection margins as recommended for skin lesions is anatomically not attain-
able, a MCC in the oral cavity has a very poor prognosis.c 2005 Elsevier Ltd. All rights reserved.
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3Introduction
Merkel cell carcinomas (MCC) are rare neuro-endo-
crine carcinomas, mostly originating in the skin.
About half of all cutaneous lesions are found on
the skin of the head and neck area, usually arising741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
oi:10.1016/j.ooe.2005.05.009
* Corresponding author. Tel.: +31 24 3614561; fax: +31 24
541165.
E-mail address: m.merkx@mkc.umcn.nl (M.A.W. Merkx).on the sun-exposed parts.1 MCCs have an aggressive
course, with early haematogenous metastasis and a
high percentage of local recurrence.2 They were
first described by Toker in 1972, and at that time
named trabecular carcinoma.3 The name MCC was
assigned in 1978 when Tang and Toker found an
ultrastructural similarity between these tumour
cells and the Merkel cells.4 There has been contro-
versy over the origin of Merkel cells. Most recently
conclusive evidence for a neural crest origin has
been obtained.5ved.
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Merkel cell carcinoma in the oral cavity: A case presentation and review of the literature 203MCC very rarely occurs on mucous membranes
of the head and neck region. In 1988 the first case
report of an oral presentation of MCC was pub-
lished.6 Until now in the English literature 13
cases of peri-oral and six cases of intra-oral man-
ifestations of MCC have been reported.7 From
these six reported intra-oral cases, two were
metastasis 8,9 from MCCs localised on the skin.
Only four were true primary intra-oral manifesta-
tions of a MCC (Table 1 6,10–12).
The purpose of this report is to describe the
first case of a MCC located in the glossopharyngeal
fold and the fifth case of a true primary intra-oral
presentation. The earlier published cases will be
reviewed.T
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A 56-year-old man was referred with a six-week
history of swallowing pain. Intra-oral inspection
revealed a small ulceration of approximately
1 cm on the right glossopharyngeal fold, with
extension onto the base of the tongue, clinically
imposing as a squamous cell carcinoma. No en-
larged lymph nodes could be palpated in the neck.
This was confirmed by ultrasonic examination.
The chest X-ray, bone scintigraphy and ultrasound
of the liver showed no abnormalities. Significant
medical history revealed two gastric perforations.
The patient smoked about one pack of cigarettes
a day. There was no alcohol abuse.
Four weeks after the initial consultation, and
two weeks after ultrasound examination of the
neck, a wide excision (clinically 1 cm tumour free
margin) was performed under general anaesthesia
and send in for examination by frozen section.
Microscopic examination supported the clinical
diagnosis of a ‘carcinoma’ without further specifi-
cation. An additional regional (regions I, II and III)
neck dissection was performed. Frozen section
examination of the neck specimen showed two
positive lymph nodes in region II. Subsequently
an extension to a modified radical neck dissection
was performed.
Pathological and immunohistochemical exami-
nation of the paraffin embedded tumour material
revealed a definitive diagnosis of oral MCC, with a
largest diameter of 1.8 cm and tumour free resec-
tion margins (>3 mm) and two positive lymph
nodes with extracapsular spreading in region II.
Postoperative radiotherapy was given to the
primary tumour site and both sides of the neck,
to a total dose of 46 Gy, in 23 daily 2 Gy fractions,
using a multiple field technique. A boost of 20 Gy
204 S.M.G.A. Hendrikx et al.was given in 10 daily fractions to the tumour site
and region II on the right side of the neck.
Two months after radiotherapy, the patient suf-
fered from pain at the right chest. A bone scintig-
raphy showed multiple metastases in ribs and
thoracic spine. Furthermore a CT-scan revealed
liver metastases. For pain reduction, beside anal-
getic medication, palliative radiotherapy to the
liver was given with a single dose of 6 Gy. Almost
one year after the primary diagnosis the patient
died due to metastatic disease.Pathology
Light-microscopy revealed a partially ulcerating tu-
mour, infiltrating deeply in the muscles of the ton-
gue. The tumour did not seem to originate from the
squamous epithelium and was composed mainly of
small cells arranged in a trabecular pattern, with
scanty cytoplasm and indistinct cell borders. The
nuclei were hyper chromatic with coarse chromatin
and small nucleoli. Mitoses, including a typical
ones, were numerous (Fig. 1a).Figure 1 (a) (HE, Obj. 40X): A representative part of the tu
corner. (b) (CD56, n-CAM, Obj. 20X): A strongly positive mem
left part of the picture and more scattered distribution of po
Obj. 40X): Many tumour cells expressed cytokeratin with a pu
cells. (d) (Thyroid transcription factor 1 (TTF-1), Obj. 2
transcription factor.Immunohistochemically tumour cells were posi-
tive for AE1/AE3, CAM 5.2, synaptophysin, cytoker-
atin 7 (CK 7) and CD56. The cells were strongly
reactive to cytokeratin 20 (CK 20) and NSE. Some
cells were focally reactive to high molecular
weight cytokeratin 34BE12. Tumour cells were neg-
ative for chromogranin, S100 and thyroid transcrip-
tion factor 1 (TTF-1) (Fig. 1b–d).
This combined histological and immunohisto-
chemical profile was consistent with a small cell
neuro-endocrine carcinoma. Negative TTF-1 and
positive cytokeratin 20 argued against primary or
metastatic small cell carcinoma of the lung25,26
and because this was the only tumour localisation,
a diagnosis of primary Merkel cell carcinoma of the
oral mucosa was made.Discussion
In 1875, the German anatomist and pathologist
Merkel first described a type of cell in the basal
layer of the epidermis, with clear cytoplasm and
associated with specialised nerve endings, and pro-mour with some striated muscle tissue in the right upper
branous expression of n-CAM in most tumour cells in the
sitive tumour cells in the right part. (c) (Cytokeratin 20,
nctuate staining pattern in a part of the positive tumour
0X): None of the tumour cells expressed the thyroid
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Merkel cells are present in hairy skin, glabrous skin,
and mucous membranes. They are found in a high
concentration on the lips, the palms of the hands,
the finger pads, the proximal nail folds, and the
dorsum of the feet.
In the mouth the number of Merkel cells depends
on the type of mucosa. The non-keratinized mucosa
of the lips and cheeks forms epithelial pegs. At the
bases of these pegs numerous Merkel cells can be
found. The keratinized mucosa of the gingiva and
hard palate forms rete pegs. In the basal layer of
these rete pegs there is also a large number of Mer-
kel cells. In the specialised mucosa of the tongue no
Merkel cells can be found.5
Histologically there are three different types of
MCC: trabecular, intermediate and small cell.13 In
the trabecular type cells are compactly arranged
in trabeculae, with relatively abundant cytoplasm
and few mitoses. This type of tumour is usually
found adjacent to adnexal structures. It is the least
frequent histologic pattern and has the best prog-
nosis. Intermediate tumours exhibit a solid and dif-
fuse growth pattern, where cytoplasm is less
abundant and mitoses and focal areas of necrosis
are frequently seen. This is the most frequent his-
tologic subtype and is clinically more aggressive.
The small cell type closely mimics small cell tu-
mours of other sites. It is organised in solid sheets
and clusters of cells. The clinical behaviour is as
aggressive as that of intermediate tumours.
A cutaneous as well as an oral MCC presents in
most cases clinically as a firm nodule, red to violet,
sometimes ulcerated and mostly painless. In a re-
cent study, Koljonen et al. found a strong female
predominance in cutaneous MCC, while other stud-
ies show an even rate or a slight male predomi-
nance.14 There might be a male predominance for
oral MCC. Only one of the five patients with a pri-
mary oral MCC described in the literature, is fe-
male, and both of the metastatic lesions where
also found in males (Table 1).
MCC has an aggressive course with early lympha-
tic and haematogenous spread. Since the tumour
often remains asymptomatic for some time, spread
has occurred in most cases at the time of diagnosis.
The diagnosis of MCC is usually made after resec-
tion of the tumour and is based on histological and
immunopathological features.
In cutaneous cases of MCC, a local recurrence
rate of 11–45% is reported. About 55–60% of the
cases develop positive lymph nodes. Distant meta-
stases, mostly to lung, liver, bones and brain, occur
in about 35% of the patients. Survival at three years
is reported at 30–70%.15–17 Vigneswaran et al. did
a review of the literature in 1992 and included 12cases of MMC, two oral and ten peri-oral tumours.
They found positive lymph nodes and/or distant
metastasis in eight of these cases.15 In our case
and the four true intra-oral cases reviewed (two
of them are the same patients included in the re-
view by Vigneswaran et al.), local recurrence oc-
curred in two patients, neck node metastases
were found in four patients and distant metastasis
in three patients. None of these patients reached a
survival of 3 years.
Resection of a cutaneous MCC with a wide mar-
gin of 2–3 cm is recommended, in combination
with an elective lymph node dissection.18 Because
of the aggressive behaviour, postoperative radio-
therapy is generally recommended with a dose of
50–60 Gy in 25–30 fractions over 5–6 weeks in
case of negative margins. For close, <3 mm, and
positive margins the dose is increased to 60–
70 Gy.19–21 The tumour appears to be fairly radio-
sensitive and radiotherapy is sometimes given as
the primary modality with curative intent.21,22
When distant metastases occur, chemotherapy
should be considered. Voog et al. reviewed the lit-
erature on the effect of chemotherapy on distant
metastasis and on locally advanced cases of
MCC.23 In a total of 107 patients, the overall objec-
tive response rate to first-line chemotherapy was
61%. The overall survival was poor with a median
of nine months for patients with metastatic disease
and two years for those with locally advanced
tumours.
The investigators also found a high rate of toxic
deaths, due to chemotherapy (7.7%). Three-year
survival for the two patient groups was 17% and
35%, respectively.
Poulsen et al. assessed the effectiveness of a
combination of chemotherapy and radiation ther-
apy in a group of 53 patients with high risk MCC
of the skin.24 Patients received a total dose of
50 Gy over 5 weeks, combined with intravenous
carboplatin and etoposide. They found a 3-year
survival of 76%, and loco regional as well as distant
control of 75%. No treatment related deaths
occurred.
In the English literature, only four cases of pri-
mary MCC in the oral cavity are described, each
one with a different location: the mucobuccal fold,
the cheek, the palate and the floor of the mouth.
Four patients including the current case, died with-
in 26 months after the diagnosis of MCC. In one
case no follow-up data were available. This poor
survival rate is not necessarily caused by a more
aggressive behaviour of MCC in the oral mucosa,
but may be due to the fact that, due to the anat-
omy, a radical excision with a 3 cm tumour free
margin is not feasible. In the cases reported close
206 S.M.G.A. Hendrikx et al.resection margins or even irradical resection was
mentioned.
Although 50% of skin MCCs appear in the head
and neck region, only four intra-oral cases are de-
scribed. This entity is not well known by head and
neck oncologists and pathologists, which may lead
to false or late diagnosis.
In conclusion, oral MCC is an aggressive tumour
with a high loco regional and distant failure rate
and poor survival.References
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